Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

177results about How to "Minimize discomfort" patented technology

Autonomous, ambulatory analyte monitor or drug delivery device

ActiveUS7004928B2Improve capillary forceMinimize coagulationAutomatic syringesMicroneedlesBiomedical engineeringElectronic equipment
The invention relates to analyte monitoring/drug (pharmaceutical agent) delivery device. The invention is suited for monitoring various blood constituents such as glucose. The device has a housing that at least partially encloses a plurality of microneedles disposed on a carrier and an electronics portion. Each microneedle is in fluid communication with a corresponding microchannel. Each microneedle is individually addressable. That is, each microneedle can be extended and retracted individually via an actuator. The electronics portion includes a processor and associated circuitry (e.g., memory, supporting electronics and the like), a motor or the like, a sensor, a power supply (e.g., battery) and optionally an interface. In general, the processor controls the operation of the device and is data communication with the actuator, motor, sensor and interface. The invention provides for autonomous operation, that is, without intervention of the user. The invention can optionally provide for calibration without intervention of the user. The invention can also provide for semi-continuous monitoring for day and night time. The invention can provide for up to four, or more, weeks of operation. The invention can provide for a device that is relative small in size, and therefore unobtrusive. The invention can also provide for device with remote control and interactive electronics. The invention may be also used for the delivery of various pharmaceutical agents including high potency drugs to minimize patient intervention and minimize discomfort.
Owner:INTUITY MEDICAL INC

Autonomous, ambulatory analyte monitor or drug delivery device

The invention relates to analyte monitoring / drug (pharmaceutical agent) delivery device. The invention is suited for monitoring various blood constituents such as glucose. The device has a housing that at least partially encloses a plurality of microneedles disposed on a carrier and an electronics portion. Each microneedle is in fluid communication with a corresponding microchannel. Each microneedle is individually addressable. That is, each microneedle can be extended and retracted individually via an actuator. The electronics portion includes a processor and associated circuitry (e.g., memory, supporting electronics and the like), a motor or the like, a sensor, a power supply (e.g., battery) and optionally an interface. In general, the processor controls the operation of the device and is data communication with the actuator, motor, sensor and interface. The invention provides for autonomous operation, that is, without intervention of the user. The invention can optionally provide for calibration without intervention of the user. The invention can also provide for semi-continuous monitoring for day and night time. The invention can provide for up to four, or more, weeks of operation. The invention can provide for a device that is relative small in size, and therefore unobtrusive. The invention can also provide for device with remote control and interactive electronics. The invention may be also used for the delivery of various pharmaceutical agents including high potency drugs to minimize patient intervention and minimize discomfort.
Owner:INTUITY MEDICAL INC

Instrument for surgically cutting tissue and method of use

An instrument for precisely cutting tissue to controlled dimensions (length, width, depth, and shape) is provided for the removal of tissue specimens from remote sites in the body of a patient, such as from the gastrointestinal tract, urinary tract, or vascular structures, or any tissue surface or soft tissue of the body. The instrument has a housing and a substantially flexible shaft extending from the housing to a distal end. The distal end of the instrument has an open cavity into which tissue is receivable. Suction can be communicated along the shaft to the distal end for distribution across the cavity utilizing a manifold having a grated tissue engaging surface with opening(s) for applying the suction, thereby pulling tissue adjacent to the distal end into the cavity against the tissue engaging surface of the manifold. One or more hollow needles are extendable from the housing through the shaft into the cavity to enable infusion of fluid, such as saline or a hemostatic agent, into the tissue. A blade in the distal end is extendable through the cavity over the manifold and across the opening to cut the tissue held by suction and stabilized by the needles in the cavity. The shape and depth of the tissue removed by the cuts is in accordance with the contour of the tissue engaging surface and the size and shape of the cavity at the distal end. The tissue so removed by the instrument may be for therapeutic intervention and / or represent a tissue specimen for biopsy suitable of diagnostic evaluation. The tissue edges in the patient's body left after cutting with this instrument readily avail themselves to apposition for enhanced healing.
Owner:LSI SOLUTIONS

Virtual monitor display technique for augmented reality environments

Methods, apparatus, and computer-readable media are described herein related to a virtual monitor display technique for augmented reality environments targeted at allowing a user of a display-enabled computing device to substitute their conventional hardware-realized display screen with a virtualized display screen of equal or better usability characteristics than the hardware-realized device. A virtual screen is rendered via a micro display in an augmented reality environment to a human user wearing a see through head mountable device. The system architecture makes use of liquid lens technology in order to adjust the relative position of the display as well as the focal distance by optical means only thereby ensuring that the virtual screen is rendered at the maximum resolution of the micro display at all times. The system architecture also comprises an occlusion matrix thereby ensuring that the virtual screen is free of ghosting. The system is configured in such a way that a display auto-hide function is triggered whenever certain threshold parameters are exceeded. The virtual monitor display technique described herein has been designed with the aim of reducing the effects simulator sickness during prolonged use of the virtual display.
Owner:VON & ZU LIECHTENSTEIN MAXIMILIAN RALPH PETER
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products